Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics, Inc. filed a resale prospectus covering up to 128,189 shares of common stock, $0.001 par value, held by former AlmataBio stockholders under a Milestone Buyout Amendment Agreement. All shares may be sold from time to time by the selling stockholders; Avalo is not selling shares and will not receive proceeds from these resales.
Avalo is a clinical-stage biotechnology company focused on therapies targeting the interleukin-1β (IL-1β) pathway for immune-mediated inflammatory diseases. Lead antibody abdakibart (AVTX-009) met the primary endpoint in the Phase 2 LOTUS trial in hidradenitis suppurativa and is planned for advancement into a registrational Phase 3 program. As of July 10, 2026, there were 52,902,989 shares of common stock outstanding; AVTX trades on Nasdaq Capital Market, last reported at $19.50 per share on July 27, 2026.
BlackRock, Inc. reports a passive ownership stake in Avalo Therapeutics Inc common stock on a Schedule 13G. BlackRock and its reporting business units beneficially own 3,415,731 shares of Avalo common stock, representing 6.5% of the class. Of these, 3,371,733 shares carry sole voting power, and all 3,415,731 shares are subject to sole dispositive power, with no shared voting or dispositive authority. The filing notes that various underlying clients have rights to dividends or sale proceeds, but no single underlying interest exceeds five percent of Avalo’s outstanding common shares.
Avalo Therapeutics, Inc. has filed a resale registration covering up to 128,189 shares of common stock held by former AlmataBio, Inc. stockholders. These shares were issued under a Milestone Buyout Option Agreement and Amendment to the merger agreement with AlmataBio.
The registration enables the selling stockholders to sell their shares from time to time; Avalo is not selling any shares and will not receive proceeds from these resales, though it will bear registration expenses. The shares may be sold through various methods at prices based on the market price of Avalo’s Nasdaq‑listed stock (symbol AVTX; last reported price $17.88 per share on July 16, 2026).
Avalo is a clinical‑stage biotechnology company focused on IL‑1β‑targeted therapies. Its lead antibody, abdakibart (AVTX‑009), met the primary endpoint in the Phase 2 LOTUS trial in hidradenitis suppurativa, with 253 adults enrolled and statistically significant HiSCR75 responses at both doses. Based on these data, the company plans to advance abdakibart into a registrational Phase 3 program.
Avalo Therapeutics, Inc. receives a Schedule 13G/A amendment disclosing that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and shared dispositive power over 9,857 shares of Avalo common stock (CUSIP 05338F306). The filing lists shared voting and shared dispositive power of 9,857 and reports 0.0% of the class. The cover information is signed under a Joint Filing Agreement dated July 2, 2026.
Avalo Therapeutics Chief Medical Officer Mittie Doyle reported an exercise-and-sell transaction in Avalo Therapeutics, Inc. common stock. On June 30, 2026, Doyle sold 4,654 shares in an open-market sale at $20.00 per share, while also exercising options to acquire a total of 4,654 shares of common stock at strike prices of $8.04 and $12.65 per share. The options exercised relate to grants that vest over four years, and all transactions were carried out under a Rule 10b5-1 trading plan adopted on November 13, 2025, indicating the trades were pre‑scheduled rather than discretionary market timing.
Avalo Therapeutics director Philip Ron M reported a grant of stock options covering 69 shares of common stock. The options were awarded on June 30, 2026 as a compensation grant, with an exercise price of $18.48 per share, are 100% vested, and expire on June 30, 2036.
Avalo Therapeutics director Kevin Robert Lind received a new stock option grant. On June 30, 2026, he was awarded options covering 1,105 shares of Avalo common stock at an exercise price of $18.48 per share. The options are 100% vested at grant and expire on June 30, 2036, leaving him with 1,105 options outstanding after this transaction.
Avalo Therapeutics director Rita Jain received a stock option grant as part of her compensation. On June 30, 2026, she was awarded options covering 1,080 shares of Avalo Therapeutics common stock at an exercise price of $18.48 per share. These options are fully vested and expire on June 30, 2036. Following this grant, she directly holds options on 1,080 underlying shares.
Avalo Therapeutics Chief Medical Officer Doyle Mittie reported an exercise-and-sell transaction in company stock. On June 23, 2026, Mittie exercised options to acquire 1,450 shares of Common Stock at $8.04 per share and sold 1,450 shares at $18.00 per share in an open-market sale. Following these transactions, Mittie directly holds 51,776 Common shares and 116,871 stock options. The filing notes that these trades were made under a Rule 10b5-1 trading plan adopted on November 13, 2025, indicating they were pre-scheduled rather than timed discretionarily.